as per annexure enclosed

Apollo Hospitals reported strong full-year results for FY2025-26 ending March 31, 2026. Consolidated revenue grew 15.8% to Rs 252,285 million, while consolidated PAT surged 33.1% to Rs 20,027 million, driven by healthcare services and digital health/pharmacy segments. Basic EPS on consolidated basis rose to Rs 135.04 from Rs 100.56. EBITDA margin expanded to 10.4% from 9.4% YoY. The Board declared a final dividend of Rs 10 per share (200%) and approved an interim dividend of Rs 10 already paid. Key corporate actions include: a composite scheme to demerge the pharmacy distribution and digital health platform into Apollo Healthtech Limited; merger of wholly-owned subsidiary Apollo Hospitals North Limited into the parent; and a transaction where Apollo Health and Lifestyle Limited will divest certain fertility/hospital assets to Kids Clinic India Limited (Cloudnine) for Rs 15,500 million (cash + equity). Statutory auditors Deloitte Haskins & Sells issued an unmodified opinion. The company holds ICRA AAA and CRISIL AA+ credit ratings.